Document:

EX-10.8

 Exhibit 10.8 

MUTUAL TERMINATION AGREEMENT 

Between 
 STC.UNM AND
ONCOTHYREON INC. 
 MUTUAL TERMINATION AGREEMENT (the “Agreement”) entered into effective May 5, 2016, (the
“Effective Date”) between STC.UNM, a New Mexico 501(c)(3) nonprofit corporation, with its principal office at 801 University Blvd. SE, Suite 101, Albuquerque, New Mexico 87106 (hereinafter referred to as “STC”) and
ONCOTHYREON INC., a Delaware corporation with a place of business at 2601 Fourth Avenue, Suite 500, Seattle, Washington 98121 (hereinafter referred to as “ONCOTHYREON”) (each of ONCOTHYREON a “Party” and together the
“Parties”). 
 As of the Effective Date, in consideration of the payments, releases, mutual covenants and premises contained
herein, the receipt and sufficiency of which are hereby acknowledged, STC and ONCOTHYREON agree: 
 BACKGROUND 

STC and ONCOTHYREON are Parties to that certain Patent License Agreement dated June 14, 2014, as amended by a First Amendment to Patent
License Agreement effective February 2, 2015, a Second Amendment to Patent License Agreement effective September 15, 2015, and a Third Amendment to Patent License Agreement effective October 13, 2015 (the “License
Agreement”). 
 The Parties now desire to terminate the License Agreement in its entirety and to release each other from certain
claims, on the terms and conditions set forth below. 
 ARTICLE I. 

TERMINATION 
 1.1
Termination. STC and ONCOTHYREON mutually agree that the License Agreement is hereby terminated in its entirety and as of the Effective Date, neither Party shall have any rights, powers, duties, or obligations under the License Agreement.
Without limiting the foregoing, as of the Effective Date: (a) the rights granted to ONCOTHYREON and any Licensed Affiliate under the License Agreement in and to the Licensed Patents shall terminate, and ONCOTHYREON and its Licensed Affiliates
disclaim all rights in and to the Licensed Patents under the License Agreement, and acknowledge and agree that they have no rights in the Licensed Patents by implication, estoppel, or otherwise; and (b) the rights granted to ONCOTHYREON under
Section 2.10 of the License Agreement related to inventions or discoveries developed pursuant to the Sponsored Research Agreement terminate. 

ARTICLE II. 
 PAYMENTS
AND COVENANTS 
 2.1 Termination Fee. ONCOTHYREON shall pay to STC a termination fee of Two Hundred Fifty Thousand Dollars
($250,000) within five (5) business days of the Effective Date. 
 2.2 License Fee. ONCOTHYREON shall pay to STC the amount of
Seventy-Five Thousand Dollars ($75,000) as a license fee within five (5) business days of the Effective Date in lieu of the license fee due June 30, 2016 and any other payments which are or may be due or come due under the License
Agreement. 

  
 Page 1 

 2.3 Payment of Patent Costs. 

ONCOTHYREON shall reimburse STC for all reasonable, documented out-of-pocket legal and other fees, costs, and expenses incurred by STC for the
prosecution and maintenance of Licensed Patents incurred prior to the Effective Date and not previously reimbursed to STC. ONCOTHYREON shall reimburse and pay to STC all such reasonable, documented out-of-pocket legal and other fees, costs, and
expenses within thirty (30) days after STC invoices ONCOTHYREON from time-to-time for the amount of such fees, costs and expenses. 

ARTICLE III. 
 MUTUAL
RELEASES 
 3.1 ONCOTHYREON, for itself and its Licensed Affiliates, irrevocably and unconditionally releases, waives and forever
discharges STC, its directors, officers, and employees, University, its Regents, officers, and employees, Sandia, its directors, officers, and employees, and the Inventors, and their respective agents, representatives, successors, and assigns, and
each of them, of and from any and all charges, complaints, grievances, actions, causes of action, suits, liabilities, obligations, promises, agreements, demands, controversies, rights, damages, costs, debts, losses, expenses (including
attorneys’ fees and costs actually incurred and to be incurred), and any other claims, however denominated or characterized, in each case solely to the extent the relevant claim: (i) arose or arises under or relates to the License
Agreement, the Licensed Patents under the License Agreement, or any publication related to the Licensed Patents authored, in whole or in part, by an Inventor that was published prior to the Effective Date; and, (ii) results from or which may
result from any matter, transaction, circumstance, act, omission or conduct, which occurred or does or shall otherwise exist at or prior to the Effective Date. In addition, ONCOTHYREON waives and releases University and STC from any duties or
obligations under Section 7 of the Sponsored Research Agreement, specifically including the grant of any nonexclusive licenses and options or rights of first refusal with respect to any invention first conceived or reduced to practice under the
Sponsored Research Agreement. The Sponsored Research Agreement will expire as of July 3, 2016 ONCOTHYREON acknowledges that all obligations of University to ONCOTHYREON have been performed under such agreement and ONCOTHYREON waives any claims
it may have against University under the Sponsored Research Agreement. University acknowledges that all obligation of ONCOTHYREON to University have been performed under such agreement and University waives any claims it may have against ONCOTHYREON
under the Sponsored Research Agreement. 
 3.2 STC irrevocably and unconditionally releases, waives and forever discharges ONCOTHYREON, its
Licensed Affiliates, and their respective directors, officers, employees, agents, representatives, successors and assigns, and each of them, of and from any and all charges, complaints, grievances, actions, causes of action, suits, liabilities,
obligations, promises, agreements, demands, controversies, rights, damages, costs, debts, losses, expenses (including attorneys’ fees and costs actually incurred and to be incurred), and any other claims, however denominated or characterized,
in each case solely to the extent the relevant claim: (i) arose or arises under or relates to the License Agreement, the Licensed Patents under the License Agreement, or any publication related to the Licensed Patents authored, in whole or in
part, by an Inventor that was published prior to the Effective Date; and, (ii) results from or which may result from any matter, transaction, circumstance, act, omission or conduct, which occurred or does or shall otherwise exist at or prior to
the Effective Date. 
 3.3 Each of STC and ONCOTHYREON expressly warrants, declares and represents to the persons or entities released by
that Party as a part of the consideration expressed herein, that before executing this Agreement, each Party fully informed itself of the terms, contents, conditions, and effects 

  
 Page 2 

 
of this Agreement; that such Party consulted with an attorney of its choice concerning the provisions of this Article III and its decision to give this release for the consideration expressed
herein; and that no promise, inducement or agreement of any kind or character has been made to such Party by the persons or entities being released hereunder or anyone acting for them, except as is expressly stated in this Agreement; such Party has
relied solely and completely upon its own judgment in executing this Agreement; each Party fully understands that this Article III is a full, complete, and final release of the matters to which it pertains, and that this Agreement contains all of
the consideration that is to be paid or provided as a result of any claim against any Party or person or entity being released hereunder whatsoever. 

3.4 Subject to Sections 3.7, 3.8, and 3.9, below, each of STC and ONCOTHYREON intend that and the releases provided above are to be construed
in the broadest, fullest, and most all-inclusive manner, and are intended to be complete and global and specifically include claims that are known or unknown, vested, fixed, contingent or conditional with respect to the matters described above and
from foreseen and unforeseen injuries and damages and the consequences thereof. Without limiting the extent thereof, each of STC and ONCOTHYREON intend that and the releases shall apply to any claim or claims arising under any local, state, or
federal law, including, but not limited to, claims based upon the patentability, invalidity, or unenforceability of the Licensed Patents, and claims based upon negligent or intentional infliction of emotional distress, negligence, negligent
misrepresentation, gross negligence, interference with contractual relations, prima facie tort, defamation, libel, invasion of privacy, breach of express or implied contract, breach of an implied covenant of good faith and fair dealing, fraud,
breach of fiduciary duty, or any other local, state, or federal statutory, regulatory, or common law right, claim, or cause of action whatsoever. 

3.5 STC agrees and covenants that it will not sue, demand arbitration, or initiate any proceeding against any person released by STC for any
claim or other matter released by STC under Section 3.2, above. ONCOTHYREON agrees and covenants that neither it nor any Licensed Affiliate will sue, demand arbitration, or initiate any proceeding against any person released by ONCOTHYREON for
any claim or other matter released by ONCOTHYREON or a Licensed Affiliate under Section 3.1, above. 
 3.6 The persons released by STC
under Section 3.2, above, and ONCOTHYREON under Section 3.1, above, are intended to be and are third Party beneficiaries with rights and remedies under this Article III. 

3.7 Notwithstanding anything to the contrary herein, nothing in this Article III shall be construed to limit either Party’s ability to
bring claims against the other Party or (in the case of ONCOTHYREON) a Licensed Affiliate for patent infringement or either Party’s ability to raise invalidity, unenforceability or non-infringement defenses against a claim for patent
infringement brought by the other Party or (in the case of ONCOTHYREON) a Licensed Affiliate, or to bring declaratory judgment counterclaims seeking a declaration of invalidity, unenforceability or non-infringement in response to a claim for patent
infringement brought by the other Party or (in the case of ONCOTHYREON) a Licensed Affiliate. 
 3.8 Notwithstanding anything to the
contrary herein, nothing in this Article III shall be construed to be a release by STC of its right to receive 28,891 shares of ONCOTHYREON stock currently held under that certain Escrow Agreement entered into in accordance with the Agreement and
Plan of Reorganization By and Among Oncothyreon, Inc., AB Acquisition (DE) Corp., Alpine Biosciences, Inc., and Mitchell H. Gold, M.D. as Stockholders’ Agent dated August 8, 2014. 

  
 Page 3 

 3.9 Notwithstanding anything to the contrary herein, nothing in this Article III shall be
construed to terminate, release or, except as expressly provided in the last sentence of Section 3.1, above, affect the rights, powers, duties, and obligations of either STC or ONCOTHYREON under the following, which shall remain in full force
and effect: 
 (a) the Mutual Nondisclosure Agreement between STC and ONCOTHYREON dated June 8, 2015,; 

(b) the Mutual Nondisclosure Agreement between STC and ONCOTHYREON dated June 8, 2015; 

(c) the Non-Disclosure and Nonuse Agreement between STC and ONCOTHYREON dated January 28, 2016, as amended; provided however, that within
ten (10) days of the Effective Date, ONCOTHYREON, in accordance with Section 5 of such agreement, shall return to STC all documents and other tangible objects representing Confidential Information disclosed to ONCOTHYREON, retaining only
one (1) archival copy thereof which may be used by ONCOTHYREON only as described in Section 5 thereof; or, 
 (d) the Sponsored
Research Agreement. 
 3.10 Subject to Section 3.7 above and except for any action, suit or proceeding arising out of the performance
or failure to perform this Agreement: (a) STC agrees that it will not take any action which is intended, or would reasonably be expected, to disparage ONCOTHYREON or its reputation; and, (b) ONCOTHYREON agrees that it will not take any
action which is intended, or would reasonably be expected, to disparage STC, UNIVERSITY, or Sandia or their reputations. For clarity, this Section 3.10 shall not prevent disclosures required pursuant to a subpoena or other court or
administrative order. 
 ARTICLE IV. 

CONFIDENTIALITY PROVISIONS 

4.1 Neither Party shall, without the express written consent of the other, for any reason or at any time disclose the terms set forth in this
Agreement, except upon a subpoena or other court order made with appropriate provision for protection of confidential information or as required by securities or other applicable laws, or the rules of any national securities exchange on which
ONCOTHYREON’s equity securities are traded, or to advisors (including financial advisors, attorneys and accountants), potential and existing investors, and others on a need to know basis, including in the case of STC, University, Sandia, and
the Inventors, in each case under circumstances that protect the confidentiality thereof on terms no less strict than those contained in this Agreement. 

4.2 STC shall maintain in confidence, and shall not use for any purpose or disclose to any third Party, information disclosed to STC by or on
behalf of ONCOTHYREON or a Licensed Affiliate prior to the Effective Date in writing and marked “Confidential” or which by its nature would reasonably be deemed to be confidential or proprietary (collectively, “Confidential
Information”) and shall not use such Confidential Information for any purpose. Confidential Information shall not include any information that: (i) was already known to the receiving Party at the time of disclosure other than under an
obligation of confidentiality, (ii) now or hereafter becomes publicly known other than through acts or omissions of STC, (iii) is disclosed to STC by a third Party under no obligation of confidentiality to ONCOTHYREON of a Licensed
Affiliate or (iv) is independently developed STC without reliance on the Confidential Information ONCOTHYREON or a Licensed Affiliate. 

  
 Page 4 

 4.3 Neither Party shall, without the express written consent of the other disclose to third
Parties the financial terms set forth in the License Agreement, except upon a subpoena or other court order made with appropriate provision for protection of confidential information or as required by securities or other applicable laws, or the
rules of any national securities exchange on which ONCOTHYREON’s equity securities are traded, or to advisors (including financial advisors, attorneys and accountants), potential and existing investors, and others, including in the case of STC,
University, Sandia, and the Inventors, on a need to know basis, in each case under circumstances that protect the confidentiality thereof on terms no less strict than those contained in this Agreement. 

ARTICLE V. 

INDEMNIFICATION 
 5.1
ONCOTHYREON shall defend, indemnify and hold the Indemnitees harmless from any and all third party claims, demands, actions and causes of action against the Indemnitees, and each of them, whether groundless or not, in connection with any and all
injuries, losses, damages or liability of any kind whatsoever arising, directly or indirectly, out of the making, using, selling, offering for sale, and/or importing of products licensed under the License Agreement by or on behalf of ONCOTHYREON or
its Affiliates, except to the extent such claims, demands, actions or causes of action result, in whole or in part, from (a) the negligent acts or omissions of an Indemnitee, or from acts or omissions of such persons for which an Indemnitee
would otherwise be strictly liable and/or (b) the invalidity and/or enforceability of the Licensed Patents. This indemnification obligation shall include, without limiting the generality of the foregoing, reasonable attorney fees and other
reasonable costs or expenses incurred in connection with the defense of any and all such claims, demands, actions, or causes of action. Notwithstanding the foregoing, ONOCOTHYREON shall have no obligation to indemnify, defend or hold harmless any
Indemnitee for any claim, demand, action or cause of action arising from conduct of any one or more Indemnitees prior to August 8, 2014. 

ARTICLE VI. 

MISCELLANEOUS 
 6.1
Definitions. Capitalized terms not defined herein have the meaning set forth in the attached Glossary. 
 6.2 Place of
Execution. This Agreement and any subsequent modifications or amendments hereto shall be deemed to have been executed in the State of New Mexico, U.S.A. 

6.3 Governing Law. This Agreement and all amendments, modifications, alterations, or supplements hereto, and the rights of the Parties
hereunder, shall be construed under and governed by the laws of the State of New Mexico without regard to its conflicts of laws principles. 

6.4 Entire Agreement. This Agreement constitutes the entire agreement between STC and ONCOTHYREON with respect to the subject matter
hereof, superseding and replacing any and all prior and contemporaneous agreements, communications, and understandings (both written and oral) regarding such subject matter and shall not be modified, amended or terminated except as herein provided
or except by another agreement in writing executed by the Parties hereto. 
 6.5 Severability. All rights and restrictions contained
herein may be exercised and shall be applicable and binding only to the extent that they do not violate any applicable laws and are intended to be limited to the extent necessary so that they will not render this Agreement illegal, invalid or
unenforceable. If any provision or portion of any provision of this Agreement shall be held to be illegal, 

  
 Page 5 

 
invalid or unenforceable by a court of competent jurisdiction, it is the intention of the Parties that the remaining provisions or portions thereof shall constitute their agreement with respect
to the subject matter hereof, and all such remaining provisions or portions thereof shall remain in full force and effect. To the extent legally permissible, any illegal, invalid or unenforceable provision of this Agreement shall be replaced by a
valid provision that will implement the commercial purpose of the illegal, invalid or unenforceable provision. 
 6.6 Costs and
Attorneys’ Fees. In the event that any action, suit or other proceeding is instituted arising out of the performance or failure to perform this Agreement (excluding for clarity any action, suit or proceeding for patent infringement brought
by either Party against the other) the prevailing party shall recover all of such party’s costs and attorneys’ fees incurred in each such action, suit or other proceeding, including any and all appeals or petitions therefrom. 

6.7 Multiple Counterparts/Electronic Execution. This Agreement may be executed in one or more counterparts all of which together
shall constitute one and the same instrument. This Agreement may be: (a) created and submitted to each Party for signature in pdf or other similar type electronic file format; and, (b) executed by manual or electronic
signature and executed signature pages may be delivered using pdf or similar type file transmitted by facsimile, electronic mail, cloud-based server, e-signature technology or other similar electronic means. When executed
and delivered as provided in this section, an electronic record of this Agreement in a form that is capable of being accurately reproduced, whether by transmission, printing, or otherwise, may be relied upon by a Party for any
purpose. 
 [Signature page follows] 

  
 Page 6 

 IN WITNESS WHEREOF, STC and ONCOTHYREON have caused this Agreement to be signed by their
duly authorized representatives as of the Effective Date. 
  

									
	STC.UNM	 		 	 ONCOTHYREON INC.

					
	By:	 	 /s/ Elizabeth J. Kuuttila
	 		 	By:	 	 /s/ Scott Peterson

		 	Elizabeth J. Kuuttila	 		 	Printed Name: Scott Peterson
		 	President & CEO	 		 	Title: Chief Scientific Officer
				
	Date:	 	May 5, 2016	 		 	Date: May 5, 2016

  
 Page 7 

 GLOSSARY 

“Indemnitees” means STC, STC’s employees, officers, and directors, University, University’s Regents, officers, and employees, Sandia,
Sandia’s employees, officers and directors, and the Inventors, and their respective heirs, executors, administrators, and legal representatives. 

“Inventors” means Eric C. Carnes, C. Jeffrey Brinker, Carlee Erin Ashley, Dan C. Wilkinson, Brian S. Wilkinson, David P. Padilla, Darren Dunphy,
Trevin Heisey, Oscar Negrete, Paul N. Durfee, Jason Townson, Yu-Shen Lin, Juewen Liu, Xingmao Jiang, David S. Peabody, Walker (Kip) Wharton, Bryce Chackerian, Cheryl L. Willman, Erin Damita Milligan, Reema R. Zeineldin, M. Houman Fekrazad, Linda A.
Felton, Terry Wu, Katharine Epler, Robert Eric Castillo, Darryl Saski, Terry Wu, Jacob Agola, Ayse Muniz, Steven Branda, Joshua Santarpia, Adrienne C. Greene, and any person named as an inventor on a Licensed Patent. 

“Licensed Affiliates” means any entity designated as a Licensed Affiliate by ONCOTHYREON as of the Effective Date in accordance with the provisions
of the License Agreement. As of the Effective Date the only Licensed Affiliate so designated by ONCOTHYREON is Alpine Biosciences, Inc. 
 “License
Agreement” means the Patent License Agreement dated June 14, 2014, as amended by a First Amendment to Patent License Agreement effective February 2, 2015, a Second Amendment to Patent License Agreement effective September 15,
2015, and a Third Amendment to Patent License Agreement effective October 13, 2015. 
 “Licensed Patents” means all rights in inventions or
discoveries covered by or embodied in the patents and patent applications listed on attached Exhibit A to the License Agreement, and all divisions, substitutions, continuations, continuations-in-part, reissues, renewals, reexaminations or extensions
thereof, any patents that issue thereon, and existing and future foreign patent applications and patents that correspond thereto. 
 “Sandia”
means Sandia Corporation, a Delaware corporation, manager and operator of Sandia National Laboratories for the United States Department of Energy under contract DE-AC04-94AL85000. 

“Sponsored Research Agreement” means the Sponsored Research Agreement by and between ONCOTHYREON as successor in interest to Alpine Biosciences,
Inc. and The Regents of the University of New Mexico dated effective July 14, 2014, as amended. 
 “University” means The Regents of the
University of New Mexico. 

  
 Page 8EX-10.2

 Exhibit 10.2 

Nevro Corp. 
 May 4,
2016 
 Mr. Michael DeMane 
 1800 Bridge Parkway 

Redwood City, CA 94065 
  

	 	Re:	Amendment to Employment Agreement 

 Dear Michael: 

This letter agreement (this “Amendment”) serves to amend that certain Employment Agreement between you and Nevro Corp. (the
“Company”), dated as of December 5, 2014 (the “Agreement”) effective as of June 1, 2016 (the “Effective Date”). 

1. Term. The Agreement, as amended hereby, and your employment with the Company shall continue in effect for a minimum of six months
from the Effective Date (i.e., through November 30, 2016) and a maximum of twelve months from the Effective Date (i.e., through May 31, 2017). Prior to November 30, 2016, the Agreement and your employment may be terminated by either
you or the Company in accordance with Section 3 of the Agreement and subject to Section 4 of the Agreement. Between November 30, 2016 and May 30, 2017, the Agreement and your employment may be terminated by either you or the
Company for any or no reason, provided that in no event will the Company have any obligations under Section 4(c) or 4(d) of the Agreement. The date the Agreement and your employment terminates in accordance with this paragraph shall be referred
to herein as the “Agreement Termination Date”. 
 2. Duties. Effective as of June 1, 2016, you shall provide
services to the Company as Executive Chairman of the Board of Directors of the Company (“Executive Chairman”) and, effective as of such date, all references in the Agreement to “Chief Executive Officer” shall be deemed to
be “Executive Chairman”. Following the Agreement Termination Date, you shall continue to serve as Chairman of the Board of Directors in a non-executive capacity and Section 3(b) of the Agreement shall be deemed amended to the extent
necessary to permit your continued service as both a member of the Board of Directors and Chairman. The Company may terminate your services as Chairman upon not less than six (6) months written notice other than for Cause (as defined in the
Agreement) for which there shall be no notice required. 
 3. Compensation and Benefits. Prior to the Agreement Termination Date, you
shall continue to be paid compensation and be eligible to participate in benefits, in each case, as set forth in Section 2 of the Agreement. For the avoidance of doubt, this means that prior to the Agreement Termination Date, you will continue
to be paid an annual base salary of $500,000 and be eligible to receive a target bonus of 75% of the base salary paid to you for the applicable year based solely upon the achievement of corporate objectives under the Company’s executive

 
bonus program and paid to you at the same time other Company executives are paid their bonus for the applicable year. For the avoidance of doubt, you do not need to be employed by the Company on
the date of payment to remain eligible for the bonus described in the preceding sentence. Following the Agreement Termination Date, you will be eligible for the compensation set forth in the Company’s non-employee director policy, based on your
service as Chairman. 
 4. Equity Awards. Prior to the Agreement Termination Date, your equity awards shall continue to vest in
accordance with their terms based on your continued services under the Agreement and shall be eligible for accelerated vesting as provided therein. On and after the Agreement Termination Date, your equity awards will continue to vest during your
service as Chairman of the Board of Directors of the Company. In the event the Company terminates your service to the Company as Chairman of the Board of Directors prior to December 31, 2018 for other than Cause, then the vesting of each
unvested equity award then held by you shall be accelerated in full as of the date of such termination. Each equity award held by you as of the date hereof, and each award agreement evidencing such equity award, will be deemed amended to the extent
necessary to reflect the terms of this Amendment. For the avoidance of doubt, this paragraph 4 shall survive termination of the Agreement. 

Your signature to this Amendment will constitute your explicit written consent to the changes to your position and the amendment to your
Agreement as provided herein, and you hereby waive any right you may have under the Agreement to resign for Good Reason (as defined under the Agreement) based on the changes set forth herein. Other than as specifically provided in this Amendment,
all terms and conditions of the Agreement continue in full force and effect. If this Amendment is acceptable to you, please sign below and return the original, fully executed Amendment to the Company. 

Sincerely, 
  

			
	NEVRO CORP.
		
	By:	 	 /s/ Andrew Galligan

		 	Name: Andrew Galligan
		 	Title: Chief Financial Officer

 By signing below, I acknowledge receipt of this Amendment and agree to its terms and conditions. 

 

					
	 /s/ Michael DeMane
	 		 	  

	Michael DeMane	 		 	May 4, 2016

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]